Morgan Stanley Maintains Overweight on Regenxbio, Lowers Price Target to $17
Morgan Stanley analyst Judah Frommer maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $18 to $17.
Login to comment